|[March 07, 2013]
Research and Markets: PharmaPoint: Prostate Cancer - Australia Drug Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/k98jl8/pharmapoint)
has announced the addition of GlobalData's new report "PharmaPoint:
Prostate Cancer - Australia Drug Forecast and Market Analysis to 2022"
to their offering.
GlobalData has released its new Country report, PharmaPoint: Prostate
Cancer - Australia Drug Forecast and Market Analysis to 2022. The recent
approvals of second-line metastatic castration-resistant prostate cancer
(mCRPC) therapies like J&J's Zytiga (abiraterone acetate) and
Medivation/Astellas' Xtandi (enzalutamide) will drive strong market
growth over the next decade. These safe and orally administered
treatments will provide safety and convenience benefits over the current
standard of care, chemotherapy with docetaxel, while prolongig the
overall survival of patients with mCRPC. The December 12, 2012 FDA
approval of Zytiga for the added indication of chemotherapy-naïve mCRPC
marks the onset of a new treatment paradigm for the disease, in which
chemotherapy is relegated to second-line therapy and beyond. For
patients with earlier-stage prostate cancer, androgen deprivation
therapy with LHRH agonists and first-generation antiandrogens remains
the standard of care for suppressing testosterone levels and temporarily
controlling the disease.
In Australia, prostate cancer is diagnosed following a patient's
presentation with symptoms, elevated PSA levels as a result of routine
screening, or an abnormal DRE. The diagnosis is confirmed after multiple
core needle biopsies or TRUS, and bone metastases are detected by CT or
bone scan. Routine PSA screening is more commonly used in Australia
compared with the 5EU, but less frequently than in the US (Baade et al.,
- Overview of RA, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the
- Detailed information on the key drugs in Australia including product
description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Australia from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and
restraints affecting the Australia Prostate cancer market.
For more information visit http://www.researchandmarkets.com/research/k98jl8/pharmapoint
Source (News - Alert): GlobalData
[ Back To Technology News's Homepage ]